Literature DB >> 14585596

Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics.

Luigi Zecca1, Fabio A Zucca, Henrik Wilms, David Sulzer.   

Abstract

Neuromelanin accumulates in dopaminergic neurons during normal aging, and in Parkinson's disease, neurons with this pigment are those that selectively degenerate. Intraneuronal neuromelanin could play a protective role during its synthesis by preventing the toxic accumulation of cytosolic catechol derivatives and, in addition, by its ability to scavenge reactive metals, pesticides and other toxins to form stable adducts. However, dying neurons in Parkinson's disease that release neuromelanin might induce a vicious cycle of chronic neuroinflammation and neuronal loss.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14585596     DOI： 10.1016/j.tins.2003.08.009

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN： 0166-2236            Impact factor:   13.837


  75 in total

1.  Neuromelanin and iron in human locus coeruleus and substantia nigra during aging: consequences for neuronal vulnerability.

Authors:  F A Zucca; C Bellei; S Giannelli; M R Terreni; M Gallorini; E Rizzio; G Pezzoli; A Albertini; L Zecca
Journal:  J Neural Transm (Vienna)       Date:  2006-04-28       Impact factor: 3.575

Review 2.  The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy.

Authors:  Alessandra Gaeta; Robert C Hider
Journal:  Br J Pharmacol       Date:  2005-12       Impact factor: 8.739

3.  Effects of age, gender, and gonadectomy on neurochemistry and behavior in animal models of Parkinson's disease.

Authors:  Andrea Tamás; Andrea Lubics; István Lengvári; Dóra Reglodi
Journal:  Endocrine       Date:  2006-04       Impact factor: 3.633

Review 4.  Functional effects of neuromelanin and synthetic melanin in model systems.

Authors:  K L Double
Journal:  J Neural Transm (Vienna)       Date:  2006-05-05       Impact factor: 3.575

5.  The surface oxidation potential of human neuromelanin reveals a spherical architecture with a pheomelanin core and a eumelanin surface.

Authors:  William D Bush; Jacob Garguilo; Fabio A Zucca; Alberto Albertini; Luigi Zecca; Glenn S Edwards; Robert J Nemanich; John D Simon
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-25       Impact factor: 11.205

Review 6.  On the key role played by altered protein conformation in Parkinson's disease.

Authors:  L F Agnati; E Baldelli; N Andreoli; A S Woods; V Vellani; D Marcellino; D Guidolin; K Fuxe
Journal:  J Neural Transm (Vienna)       Date:  2008-06-05       Impact factor: 3.575

7.  Norharman-induced motoric impairment in mice: neurodegeneration and glial activation in substantia nigra.

Authors:  A Ostergren; A Fredriksson; E B Brittebo
Journal:  J Neural Transm (Vienna)       Date:  2005-08-03       Impact factor: 3.575

8.  Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson's disease.

Authors:  Wei Zhang; Kester Phillips; Albert R Wielgus; Jie Liu; Alberto Albertini; Fabio A Zucca; Rudolph Faust; Steven Y Qian; David S Miller; Colin F Chignell; Belinda Wilson; Vernice Jackson-Lewis; Serge Przedborski; Danielle Joset; John Loike; Jau-Shyong Hong; David Sulzer; Luigi Zecca
Journal:  Neurotox Res       Date:  2009-12-03       Impact factor: 3.911

9.  The role of dopamine oxidation in mitochondrial dysfunction: implications for Parkinson's disease.

Authors:  Teresa G Hastings
Journal:  J Bioenerg Biomembr       Date:  2009-12       Impact factor: 2.945

Review 10.  Modulation of alpha-synuclein aggregation by dopamine: a review.

Authors:  Su Ling Leong; Roberto Cappai; Kevin Jeffrey Barnham; Chi Le Lan Pham
Journal:  Neurochem Res       Date:  2009-05-15       Impact factor: 3.996
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.